Dyax Corp
http://www.dyax.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dyax Corp
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?
Latigo Raises $135m To Channel Vertex
The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.
What’s New, And What’s Coming, In Radiopharmaceuticals
Novartis is the leader when it comes to targeted cancer therapies incorporating radioisotopes. But plenty of companies are trying to break in to this market.
Emerging Company Profile: Chinese siRNA Specialist Sirius All In On Cardiovascular Disease
Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
- Molecular Diversity
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice